Você procurou por: patsiendist (Estoniano - Inglês)

harva patsiendist
gastrointestinal disorders common:

eemaldage süsteem patsiendist
remove system from patient

463 patsiendist 63% olid mehed.
of 463 patients, 63% were male.

väga sage sage aeg- ajalt patsiendist
very common common uncommon rare very rare

126 patsiendist 96 said raltegraviiri soovitatud annuses.
of the 126 patients, 96 received the recommended dose of raltegravir.

107 patsiendist 63 loeti liposomaalsetele antratsükliinidele resistentseks.
of the 107 patients, 63 patients were considered resistant to liposomal anthracyclines.

126 patsiendist 96 said isentress’i soovitatud annuses.
of the 126 patients, 96 received the recommended dose of isentress.

väga sagedased kõrvaltoimed (rohkem kui ühel 10 patsiendist):
very common side effects (more than one in 10 patients): • loss of appetite, weight loss (especially when combined with the antiepileptic medicine sodium valproate); • insomnia (sleeplessness), drowsiness; • ataxia (inability to coordinate muscle movements), hypotonia (low muscle strength), dystonia (muscle disorders).

278 randomiseeritud patsiendist sai 277 vähemalt 1 annuse uuringuravimit.
of the 278 patients randomised, 277 patients received at least 1 dose of study drug.

sagedased kõrvaltoimed (ühel 100 patsiendist kuni ühel 10 patsiendist):
common side effects (between one in 100 patients and one in 10 patients): • raised levels of liver enzymes, especially when given with either of the antiepileptic medicines carbamazepine and sodium valproate; • aggressiveness, irritability, agitation, hyperexcitability (state of being unusually excitable); • sleep disorders (abnormal sleeping);

kuueteistkümnest madala tiitriga patsiendist alustas it- ravi kümme.
of the 16 patients with low titres, it

vähem kui 1 patsiendil 10000 ravitud patsiendist, sealhulgas üksikjuhud
dryness of the throat or mouth, loss of appetite. fungal infections of the gullet, inflammation of the pancreas, inflammation of the tongue.

49 varem nukleosiididega ravitud 51 patsiendist oli kasutanud varem lamivudiini.
forty-nine of the 51 nucleoside-experienced patients were previously treated with lamivudine.

213 patsiendist, kelle kohta tulemus oli teada, jäi ellu 58%.
of the 213 patients in whom the outcome was known the survival was 58%.

126 patsiendist 96 said raltegraviiri soovitatud annuses (vt lõik 4.2).
of the 126 patients, 96 received the recommended dose of raltegravir (see section 4.2).

sagedad kõrvaltoimed (võivad esineda ühel kuni kümnel igast 100 patsiendist):
common side effects (between 1 and 10 in every 100 people are likely to get these):

(võivad tekkida kuni 1-l igast 100-st ravitud patsiendist)
(may affect up to 1 in every 100 patients treated)

Üheksast ravile mitteallunud patsiendist neli (44 %) saavutas täieliku ravivastuse nelarabiinile.
four (44 %) of the nine refractory patients experienced a complete response to nelarabine.

(võivad tekkida vähemalt 1-l igast 10-st ravitud patsiendist)
(may affect at least 1 in every 10 patients treated)

nendest 117 patsiendist 61 patsienti olid fip1l1-pdgfralfa liit-kinaas-positiivsed.
in 61 of these 117patients fip1l1- pdgfrα fusion kinase was identified.